Clinical updates, including trial initiations, enrollment status and data readouts and publications: Perimeter Medical Imaging AI, Trisalus Life Sciences.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aidoc, AMDI, Endologix, Medtronic, Ontrak, Spineart, Wheeler Bio.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: AIOmega, Biosense Webster, Femasys, Nevro, Onward Medical, Vapotherm.
The $110 million that Medical Microinstruments Inc. (MMI) recently raised in its series C funding round is testament to its unique position in microsurgery, said Olivier Litzka, a board member at MMI and a partner at Andera Partners. “There are not many companies actually working in that space in robotics,” he told BioWorld.
“The market stinks,” Brian Johnson, a partner and vice chair of Wilmerhale’s corporate practice group, told a U.S. SEC advisory committee Feb. 27, as he painted a gloomy picture of last year’s IPO landscape in the U.S. While the scene was a little brighter than in 2022, a few key indicators could be worrisome, especially the median offering size, which is predictive of the strength of the IPO market, Johnson said
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Cardiai, Centogene, Fire1, Kore, Medical Guardian, Reveal Genomics, Smith & Nephew.
The U.S. National Institutes of Health reported the launch of a network for clinical trials that will examine the utility of cancer screening tools, which will start with a pilot study of multi-cancer detection (MCD) tests.
The U.S. Patent and Trademark Office (PTO) has released a guidance to aid patent examiners in dealing with questions of obviousness in patent applications, but patent attorney Michael Borella told BioWorld that this new guidance could resurrect the law of unintended consequences. Borella, a partner in the Chicago office of McDonnell Boehnen Hulburt & Berghoff LLP, said the guidance might lead to more inappropriate rejections of patent claims for obviousness, and thus make the process of obtaining a clean patent more difficult, not less.
RSS
